Glucocorticoid teratogenesis in mouse whole embryo culture

A metabonomic approach to analyze the dexamethasone-induced cleft palate in mice

Mice models are an important way to understand the relation between the fetus with cleft palate and changes of maternal biofluid. This paper aims to develop a metabonomics approach to analyze dexamethasone-induced cleft palate in pregnant C57BL/6J mice and to study the relationship between the change of endogenous small molecular metabolites in maternal plasma and the incidence of cleft palate. To do so, pregnant mice were randomly divided into two groups. The one group was injected with dexamethasone. On E17.5th day, the incident rates of cleft palate from embryos in two groups were calculated. The ¹H-NMR spectra from the metabolites in plasma in two groups was collected at same time. Then the data were analyzed using metabonomics methods (PCA and SIMCA). The results showed that the data from the two groups displayed distinctive characters, and the incidence of cleft palate were significantly different (P < .005). To conclude, this study demonstrates that the metabonomics approach is a powerful and effective method in detecting the abnormal metabolites from mother in the earlier period of embryos, and supports the idea that a change from dexamethasone induced in maternal metabolites plays an important role in the incidence of cleft palate.

A preliminary study on the teratogenesis of dexamethasone and the preventive effect of vitamin B12 on murine embryonic palatal shelf fusion in vitro

Excessive dexamethasone (Dex) administrated into pregnant mice during critical periods of palatal development can produce a high incidence of cleft palate. Its mechanisms remain unknown. Vitamin B12 has been shown to antagonize the teratogenic effects of Dex, which, however, remains controversial. In this study, we investigated the effects of Dex and vitamin B12 on murine embryonic palatal shelf fusion using organ culture of murine embryonic shelves. The explanted palatal shelves on embryonic day 14 (E14) were cultured for 24, 48, 72 or 96 h in different concentrations of Dex and/or vitamin B12. The palatal shelves were examined histologically for the morphological alterations on the medial edge epithelium (MEE) and fusion rates among different groups. It was found that the palatal shelves were not fused at 72 h or less of culture in Dex group, while they were completely fused in the control and vitamin B12-treated groups at 72 and 96 h, respectively. The MEE still existed and proliferated. In Dex+vitamin B12 group the palatal shelves were fused at each time point in a similar rate to controls. These results may suggest that Dex causes teratogenesis of murine embryonic palatal shelves and vitamin B12 prevents the teratogenic effect of Dex on palatogenesis on murine embryos in vitro.

Embryonic palatal responses to teratogens in serum-free organ culture

This study examines development of rat, mouse, and human embryonic palates in submerged, serum-free organ culture. The concentration-response profiles for retinoic acid (RA), triamcinolone (TRI), hydrocortisone (HC), dexamethasone (DEX), and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) were examined and the mechanisms of clefting in vitro were compared to observed in vivo responses. Craniofacial regions were dissected on gestational day (GD) 12 for mice and GD 14 for rat, and cultured for 3-4 days in Bigger's BGJb medium in flasks flushed with 50% O2, 45% N2, 5% CO2. Growth and fusion of secondary palates were scored under a dissecting microscope. In serum-free control medium, mouse and rat palatal fusion occurred within the 4-day culture period. Supplementing with fetal bovine serum (FBS) in excess of 1% interfered with growth and fusion in control medium. RA significantly inhibited fusion of mouse and rat palates at 5 x 10(-9) and 1 x 10(-10) M, respectively, with RA-induced clefting related to abnormal proliferation and differentiation of medial epithelia. In contrast, glucocorticoid-induced clefting was due to concentration-dependent inhibition of shelf growth. TRI significantly inhibited fusion at 4 x 10(-5) M, and 1 x 10(-4) M DEX or HC, inhibited fusion of 19 and 42% of shelves, respectively. The response rate for DEX in the presence of 1% FBS was increased (42% unfused). TCDD clefting was due to altered medial epithelial differentiation and 1 x 10(-8) M TCDD affected 36% of CD-1 mouse, 23% of C57BL/6N mouse, and 47% of F344 rat palates. When the medium was supplemented with 1% FBS, selenium, transferrin, and additional glutamine, the response of C57BL/6N embryos increased to 75%. This rate is similar to that reported for Trowell's-type cultures with IMEM:F12 medium and 1% FBS. The increased responsiveness to DEX or TCDD in the presence of serum suggests that an unknown factor in serum may be required for full activity. Three human embryonic palatal explants (GD 52 or 53) were cultured for 3-6 days and fused during culture. The present study demonstrates that serum-free organ culture supports development of mouse, rat, and human palatal explants. The present study demonstrates the capacity of this organ culture system to model palatogenesis for several species, and to distinguish between various mechanisms of clefting as presented through selected model compounds. This model should be useful for exploring mechanisms of activity at a cellular and molecular level.

Biologic basis for a risk assessment model for cleft palate

A biologic model for palatogenesis is presented, intended as a basis for risk assessment. It comprises a sequence of developmental stages: growth and migration of neural crest cells, downward growth of palatal buds, elevation of palatal shelves, and differentiation of the epithelium followed by shelf fusion. Several events representing these stages and amenable to mathematical translation may be measurable in the form of biomarkers such as DNA and protein synthesis, phospholipid metabolism, and signal transducing systems. Interrupting components of the model will result in cleft palate. Teratogens with known mechanisms of action are compared with the model. The quantitative risk of cleft palate is conceived as a sequence of mathematical probabilities that any stage of the model runs an abnormal course. Stage-specific probabilities are determined by a chemical's potency and dose, and by duration of exposure and gestational age. Species or strain sensitivity may be expressed as quantitative differences in model parameters. Although the model is designed for cleft palate, the risk model may also estimate a multiple response risk to the same exposures.

Glucocorticoid teratogenesis in the developing nephron

Although the induction of polycystic kidney disease by neonatal glucocorticoid treatment has been extensively documented, there are no data on induction of polycystic kidney disease with fetal exposure to glucocorticoids. We injected groups of pregnant Swiss Webster albino mice subcutaneously with 250 mg/kg of hydrocortisone acetate on individual days from days 1 to 19 of gestation. A control group received an equal volume of saline. Histologic analysis of 1,522 kidneys from the offspring of these animals revealed no evidence of polycystic kidneys in the control group or in offspring of animals injected before day 11 of pregnancy. A bimodal distribution of cystic kidney disease was noted in the remaining animals, with highest prevalence after injection on day 12 (50.8%) and day 17 (34.3%). We conclude that 250 mg/kg of glucocorticoids may induce polycystic kidney disease in utero, but possibly only during critical periods of metanephric development.

Elevated glucocorticoid receptor levels in lymphocytes of children with the fetal hydantoin syndrome (FHS)

Our recent studies of the teratogenic mechanisms of phenytoin (DPH) and glucocorticoids in mice have indicated that DPH utilizes the anti-inflammatory pathway of glucocorticoids in producing congenital defects, such as cleft palate. This pathway is influenced by H-2 and H-3 histocompatibility-linked genes in the mouse, such that congenic strains have H-2 or H-3 alleles that confer susceptibility to DPH-induced congenital defects, and susceptible H-2 congenic strains have high glucocorticoid receptor levels. However, other H-2 or H-3 alleles confer resistance to these defects in their otherwise genetically identical congenic partner strains, and "resistant" H-2 alleles are associated with low levels of these receptors. To determine whether this animal work is applicable to the human, we have sought to investigate whether the level of glucocorticoid receptors in circulating lymphocytes of children with the fetal hydantoin syndrome (FHS) is as it is in the animals. We found that children with FHS had glucocorticoid receptor levels significantly elevated above those of unaffected children with similar DPH exposure in control families. The receptor level of affected children was also significantly elevated above that of fathers of children with the FHS and of fathers and mothers of control children. These findings are consistent with those documented in the animal models and suggest that an elevated level of glucocorticoid receptors in lymphocytes may be a marker for susceptibility to the FHS syndrome.

A new method to express embryotoxic data obtained in vitro on whole murine embryos

This report proposes to express the effect of drugs in the whole embryo culture system by a new method using an intrinsic reference. Percentages of malformed embryos or other defects in development, expressed as percentages of controls, are plotted against concentrations of the drug expressed as percentages of the concentration inducing 50% embryolethality (ELC50). It is suggested that the slope generated by this method is directly related to the intensity of the in vitro teratogenic potential of the agent and allows an estimation of the specific interference with developmental processes. The method has been applied to data obtained from the literature and pertaining to 22 drugs. The slope generated by these drugs varied widely. The effect of these drugs could be meaningfully compared in spite of the wide range of ELC50 displayed by the drugs. In addition, results obtained for two drugs in different laboratories using different methods and species were in fair agreement when they were compared by using the proposed method. Finally, it is suggested that the method provides an improved means to inquire if there is any relevance of in vitro data to teratological results obtained in vivo.

The incidence of tail flexion to the left side in mouse embryos

The tail was flexed towards the left side of the body in 5.2 and 6.2% of ICR mouse embryos at 10.5 and 11.5 days of gestation respectively. Body weights of these embryos did not differ from their littermates with right-sided tail flexion. The flexion to the left may be an easily detectable parameter of variation in the morphology of mouse embryos at midgestation.

Effects of changes in Ca2+ concentration of the culture medium on the in vitro development of 11-day mouse embryos

The present study was designed to examine the effects of changes in Ca2+ concentration in a culture medium on the development of 11-day mouse embryos (plug day = day 0). The embryos were individually cultured for 24 hours by rotating bottles using a culture medium of 25% rat serum and 75% Waymouth's medium. The Ca2+ concentration was changed by adding EGTA or CaCl2 to the Waymouth's medium. The Ca2+ concentrations examined were 0.5, 1.0, 1.5, 2.0, and 3.0 mM in 95% oxygen and 1.0, 2.0, and 3.0 mM in 60% oxygen. Development of embryos was evaluated on the basis of heartbeat, survival, growth, and differentiation. In 95% oxygen, the best survival was obtained at 1.5 mM Ca2+, while growth and differentiation were little affected by changes in Ca2+ concentrations except at 0.5 mM. In 60% oxygen, rhythmical heartbeats were difficult to maintain in many of the embryos at all Ca2+ concentrations examined, although reasonable development was obtained at 3.0 mM Ca2+. The optimal conditions were a culture medium containing 1.5 mM Ca2+ and an oxygen concentration of 95%. The addition of Waymouth's medium to the rat serum is useful in controlling the Ca2+ concentration of the culture medium.

Arachidonic acid and male genital differentiation

Arachidonic acid (AA) prevents neural tube/defects, cleft palate, and micrognathia in the rat models of diabetic embryopathy and neural tube defects in the mouse embryo culture model. In this study, the involvement of AA in the male genital differentiation was described. These observations raise the complementary possibility that the AA-prostaglandin biochemical pathway may be a major mechanism mediating many embryonic events that involve cellular movement and fusion.

Application of the post-implantation rat embryo culture system to in vitro teratogenicity testing

Originally developed for studying basic mechanisms in developmental biology, the post-implantation embryo culture system has been extended and applied to the testing of chemicals in the field of prenatal toxicology. The endpoints used in a procedure that has been developed for the routine short-term assessment of teratogenicity in vitro are growth (crown-rump length), differentiation (somite number) and morphology (together with measurement of yolk-sac growth and vascularization) in rat embryos explanted on day 9.5 of gestation and cultured for 48 hr in 100% homologous rat serum containing the test compound. Studies involving exposure to trichlorophenoxyacetic acid and to acetylsalicylic acid demonstrate the ability of this system to distinguish between non-specific toxicity and specific effects on development.

The arachidonic acid cascade is involved in the masculinizing action of testosterone on embryonic external genitalia in mice

We have evaluated whether the arachidonic acid cascade may be involved in the folding and fusion of the penis and scrotum in masculine differentiation, a possibility raised by recent observations of the involvement of the arachidonic acid cascade in the analogous embryonic processes of elevation and fusion of the palatal shelves and of folding and fusion of the neural tube. To test this hypothesis, during embryonic masculine differentiation in mice of the B10.A strain, we administered certain agents that produce blockade of masculinization. We report that arachidonic acid can reverse the inhibition of masculine development in male embryos produced by estradiol-17 beta or by cyproterone acetate, an androgen receptor-site blocker, and that such reversal can be prevented by an inhibitor of cyclooxygenase, such as indomethacin. We have also found that agents that block the arachidonic acid cascade at the level of phospholipase A2 (cortisone, phenytoin) or at the level of cyclooxygenase (indomethacin, aspirin) also block masculine differentiation and that such antimasculinization is reversed by arachidonic acid. The masculinization of male embryos is inhibited by indomethacin and aspirin, and the masculinization of female embryos produced by exogenous testosterone is prevented by indomethacin. These findings provide evidence that the mechanism by which testosterone organizes the genitalia involves a role of the arachidonic acid cascade leading to prostaglandins at a critical period of development and that interference with testosterone synthesis or action leads to a teratogenic deficiency of arachidonic acid during this time in the genital anlagen.